Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0002042266 XXXXXXXX LIVE 1 Common Stock, $0.0001 par value per share 04/30/2025 false 0001228627 67577R102 Opus Genetics, Inc. 8 Davis Drive, Suite 220 Durham NC 27709 Russell Kelley, Managing Dir. 919-610-2064 Foundation Fighting Blindness RD Fund 223 S. West Street, Suite 900 Raleigh NC 27603 0002042266 N Foundation Fighting Blindness Retinal Degeneration Fund b OO N DE 0 9492171 0 9492171 9492171 N 15.9 CO OO Percent of class represented in Row (11) is based on 59,629,197 shares of common stock, $0.00001 par value per share (the "Common Stock") of Opus Genetics, Inc., a Delaware corporation (the "Issuer") outstanding, which is the sum of the converted Series A non-voting convertible preferred stock, $0.0001 par value per share (the Preferred Stock") plus 45,483,823 shares of Common Stock outstanding as of March 27, 2025, as reported in the Issuer's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 31, 2025. Y Foundation Fight Blindness, Inc. b OO N MD 0 9492171 0 9492171 9492171 N 15.9 CO Percent of class represented in Row (11) is based on 59,629,197 shares of the Issuer's Common Stock outstanding, which is the sum of the converted Preferred Stock plus 45,483,823 shares of the Issuer's Common Stock outstanding as of March 27, 2025, as reported in the Issuer's Annual Report on Form 10-K filed with the SEC on March 31, 2025. Common Stock, $0.0001 par value per share Opus Genetics, Inc. 8 Davis Drive, Suite 220 Durham NC 27709 This Amendment No. 1 on Schedule 13D amends the statement on Schedule 13D, dated October 29, 2024 (the "Original Schedule 13D"), which relates to the Common Stock of the Issuer, filed by the Reporting Persons. This Amendment No. 1 on Schedule 13D is being filed to show the change in percentage of beneficial ownership held by the Reporting Persons as a result of automatic conversion of the Issuer's Preferred Stock on the third business day after the date that the Issuer's stockholders approved the conversion of the Preferred Stock into shares of the Issuer's Common Stock, which approval occurred on April 30, 2025. 9,492,171 - 15.9% 9,492,171 Reference is made to the discussion in Item 3 of the Original Schedule 13D and the Form 3 filed by the Reporting Person on October 29, 2024 with the SEC pursuant to Section 16 of the Act and is available on the SEC's website at www.sec.gov. The information reported in the filings are expressly incorporated herein. Not Applicable. Exhibit 5 - Joint Filing Agreement by and between the Reporting Persons. Foundation Fighting Blindness Retinal Degeneration Fund /s/ Russell Kelley Russell Kelley, Managing Director 05/06/2025 Foundation Fight Blindness, Inc. /s/ Jason Menzo Jason Menzo, Chief Executive Officer 05/06/2025